Nature Immunology. 2 (2): 172-180. Doi:10.1038/84282 > 자유게시판

Cell therapy (additionally called cellular therapy, cell transplantation, or cytotherapy) is a therapy during which viable cells are injected, grafted or implanted into a patient so as to effectuate a medicinal effect,[1] for example, by transplanting T-cells capable of preventing cancer cells through cell-mediated immunity in the course of immunotherapy, https://therapywhitstemcells.com/ or grafting stem cells to regenerate diseased tissues.

Cell therapy originated within the nineteenth century when scientists experimented by injecting animal materials in an try to stop and treat sickness.[2] Although such attempts produced no optimistic profit, further analysis found within the mid twentieth century that human cells could possibly be used to help forestall the human body rejecting transplanted organs, leading in time to successful bone marrow transplantation as has grow to be frequent practice in therapy for patients which have compromised bone marrow after illness, infection, radiation or chemotherapy.[3] In current many years, nonetheless, stem cell and cell transplantation has gained significant interest by researchers as a potential new therapeutic strategy for a wide range of diseases, particularly for degenerative and immunogenic pathologies.

Background

Cell therapy may be outlined as therapy during which cellular materials is injected or in any other case transplanted right into a patient.[1] The origins of cell therapy can maybe be traced to the nineteenth century, when Charles-Édouard Brown-Séquard (1817-1894) injected animal testicle extracts in an attempt to stop the effects of aging.[2] In 1931 Paul Niehans (1882-1971) - who has been called the inventor of cell therapy - tried to cure a patient by injecting material from calf embryos.[1] Niehans claimed to have handled many people for most cancers using this method, although his claims have never been validated by analysis.[1]

In 1953 researchers found that laboratory animals could possibly be helped not to reject organ transplants by pre-inoculating them with cells from donor animals; in 1968, in Minnesota, the primary successful human bone marrow transplantation occurred.[3] In newer work, cell encapsulation is pursued as a way to shield therapeutic cells from the host immune response. Recent work consists of micro-encapsulating cells in a gel core surrounded by a solid, but permeable, shell.[4]

Bone marrow transplants are the most typical and properly established cell transplantation therapies. The first recording of a successful bone marrow transplant, dates back to 1956 by dr. E Donnall Thomas, who treated a leukemia affected person with their twin-siblings bone marrow.[5] Normally, for patients presenting broken or destroyed bone marrow, for example after chemotherapy and/or radiation for acute myeloid leukemia (AML), bone marrow derived cells will be infused into the patients blood stream. Here the injected cells are able to dwelling into the affected bone marrow, combine, proliferate and recuperate or re-establish its biological perform e.g. the haematopoiesis. Annually an estimated 18,000 patients require potentially life-saving bone marrow transplants within the US.[6] For a long time, bone marrow transplantation was the only clinically relevant methodology of cell transplantation, nevertheless, for the reason that nineties, cell therapy has been investigated for a large scale of pathologies and disorders. Cell therapy offered a novel strategy to effectuate therapeutic efficacy. Previously, medical brokers could only be effective by directing and inducing the patients personal cells. However, in many diseases and disorders, cell are compromised by e.g. senescence, restricted blood supply (ischemia), inflammation, or simply a reduction within the number of cells. Cell therapy gives a brand new strategy that supports the introduction of new and energetic cells to restore beforehand compromised or deteriorated tissue- and organ buildings. As such, in recent occasions, cell therapy has been acknowledged as an essential field within the therapy of human disease,[7] and investigations are ongoing in articular cartilage,[8] mind tissue,[9] spine,[10] heart,[11] cancers,[12] and so on. As a consequence cell therapy as a method has been attracting significant investments by business entities which suggest strong prospects for future growth.[13][14]

In 2021 Atara biotherapeutics turned the first ever allogeneic T cell therapy company to be reviewed by any regulatory company in the world (EMA)

Mechanisms of action

Cell therapy is focused at many clinical indications in a number of organs and by several modes of cell supply. Accordingly, the specific mechanisms of action involved within the therapies are huge-ranging. However, there are two predominant principles by which cells facilitate therapeutic motion:

1. Stem, progenitor, or mature cell engraftment, differentiation, and lengthy-time period alternative of broken tissue. In this paradigm multipotent or unipotent cells differentiate into a specific cell sort within the lab or after reaching the location of injury (through native or systemic administration). These cells then integrate into the positioning of damage, changing broken tissue, and thus facilitate improved operate of the organ or tissue. An example of this is the use of cells to substitute cardiomyocytes after myocardial infarction,[15][16] to facilitate angiogenesis in ischemic limb disease,[17] or the production of cartilage matrix in intervertebral disc degeneration.[18][19]2. Cells which have the capacity to launch soluble components equivalent to cytokines, chemokines, and development factors which act in a paracrine or endocrine manner. These factors facilitate self-healing of the organ or region by inducing local (stem) cells or attracting cells to migrate in the direction of the transplantation site. Early cell passages have been shown to be extra environment friendly paracrine activity than later passages.[20][21] The delivered cells (via native or systemic administration) stay viable for a relatively brief period (days-weeks) and then die. This includes cells that naturally secrete the relevant therapeutic factors, or which undergo epigenetic adjustments or genetic engineering that causes the cells to release large quantities of a specific molecule. Examples of this embrace cells that secrete elements which facilitate angiogenesis, anti-inflammation, and anti-apoptosis.[22][23][24] This mode of action is proposed by firms corresponding to Pluristem and Pervasis that use adherent stromal cells or mature endothelial cells to deal with peripheral artery disease and arteriovenous entry complications.[25][26]
Cell therapy strategies

Allogeneic

In allogeneic cell therapy the donor is a different particular person to the recipient of the cells.[27] In pharmaceutical manufacturing, the allogenic methodology is promising as a result of unmatched allogenic therapies can kind the premise of "off the shelf" merchandise.[28] There may be analysis interest in making an attempt to develop such products to deal with conditions together with Crohn's illness[29] and a variety of vascular circumstances.[30]

Autologous

In autologous cell therapy, cells are transplanted which might be derived from the patients personal tissues. Multiple clinical studies are ongoing that acquire stromal cells from bone-marrow, adipose tissue, or peripheral blood to be transplanted at websites of injury or stress; which is being actively explored for e.g. cartilage[31] and muscle[32] restore. It may also involve the isolation of matured cells from diseased tissues, to be later re-implanted at the identical or neighboring tissues; a technique being assessed in clinical trials for e.g. the spine in preventing disc reherniation or adjoining disc illness.[33][34] The good thing about an autologous strategy is that there is proscribed concern for immunogenic responses or transplant rejection. Nevertheless, an autologous technique is usually pricey resulting from patient-by-affected person processing, thus stopping the choice to create massive quality-managed batches. Moreover, autologous methods typically do not allow for product quality and effectiveness testing prior to transplantation, because it is very donor (thus patient) dependent. This is a particular concern as usually the patient functioning as donor is diseased, and this can impact cell potency and high quality.

Xenogeneic

In xenogeneic cell therapies, the recipient will receive cells from another species. For instance, the transplantation of pig derived cells to humans. Currently, xenogeneic cell therapies primarily contain human cell transplantation into experimental animal fashions for evaluation of efficacy and security,[17] nevertheless future advances may potentially enable xenogeneic methods to humans as properly.[35]

Research into human embryonic stem cells is controversial, and regulation varies from country to country, with some countries banning it outright. Nevertheless, these cells are being investigated as the basis for plenty of therapeutic functions, including possible treatments for diabetes[36] and Parkinson's illness.[37]

Neural stem cell therapy

Neural stem cells (NSCs) are the subject of ongoing analysis for doable therapeutic functions, for example for treating numerous neurological disorders similar to Parkinson's illness and Huntington's illness.[38]

Mesenchymal stem cell therapy

MSCs are immunomodulatory, multipotent and quick proliferating and these distinctive capabilities mean they can be used for a variety of remedies together with immune-modulatory therapy, bone and cartilage regeneration, myocardium regeneration and the treatment of Hurler syndrome, a skeletal and neurological disorder.[39]

Researchers have demonstrated using MSCs for the remedy of osteogenesis imperfecta (OI). Horwitz et al. transplanted bone marrow (BM) cells from human leukocyte antigen (HLA)-identical siblings to patients with OI. Results present that MSCs can develop into normal osteoblasts, resulting in fast bone growth and diminished fracture frequencies.[40] A newer clinical trial confirmed that allogeneic fetal MSCs transplanted in utero in patients with extreme OI can engraft and differentiate into bone in a human fetus.[41]

Besides bone and cartilage regeneration, cardiomyocyte regeneration with autologous BM MSCs has additionally been reported lately. Introduction of BM MSCs following myocardial infarction (MI) resulted in vital discount of broken areas and enchancment in heart function. Clinical trials for treatment of acute MI with Prochymal by Osiris Therapeutics are underway. Also, a clinical trial revealed enormous improvements in nerve conduction velocities in Hurler's Syndrome patients infused with BM MSCs from HLA-equivalent siblings.[42]

Hematopoietic stem cells (HSCs), derived from bone marrow or blood, are cells with the abilities to self-renew and to differentiate into all forms of blood cells, especially these involved in the human immune system. Thus, they can be used to treat blood and immune disorders. Since human bone marrow grafting was first revealed in 1957,[43] there have been vital developments in HSCs therapy. Following that, syngeneic marrow infusion[44] and allogeneic marrow grafting[45] had been carried out efficiently. HSCs therapy can also render its cure by reconstituting broken blood-forming cells and restoring the immune system after excessive-dose chemotherapy to eradicate disease.[46]

There are three varieties of HSC transplantation: syngeneic, autologous, and allogeneic transplants.[39] Syngeneic transplantations occur between identical twins. Autologous transplantations use the HSCs obtained immediately from the affected person and therefore keep away from complications of tissue incompatibility; whereas allogeneic transplantations involve the usage of donor HSCs, either genetically associated or unrelated to the recipient. To decrease the risks of transplant, which include graft rejection and graft-versus-host illness (GVHD), allogeneic HSCT should satisfy compatibility at the HLA loci (i.e. genetic matching to reduce the immunogenicity of the transplant).

In addition to bone marrow-derived HSCs, the use of alternative sources such as umbilical cord blood (UCB) and peripheral blood stem cells (PBSCs) has been rising. Compared with bone marrow-derived HSC recipients, PBSC recipients who had myeloid malignancies reported a quicker engraftment and higher general survival.[47] The usage of UCB requires much less stringent HLA loci matching, although the time of engraftment is longer and graft failure rate is greater.[48][49]

Differentiated or mature cell transplantation

Alternative to stem- or progenitor cells, investigations are exploring the transplantation of differentiated cells that only possess low or no proliferation ability. This tends to involve specialised cells capable of facilitate particular perform in the patients body (for example, transplantation of cardiomyocytes[50] to restore heart perform or islet cell transplantation[51] for establishing insulin homeostasis in diabetes patients) or help/regenerate the extracellular matrix manufacturing of particular tissues (for instance intervertebral disc repair by transplanting chondrocytes[10]).

Alternative medicine

In various drugs, cell therapy is defined because the injection of non-human cellular animal materials in an try to treat sickness.[1] Quackwatch labels this as "senseless", since "cells from the organs of one species cannot substitute the cells from the organs of other species" and because a variety of serious adverse effects have been reported.[52] Of this alternative, animal-based mostly form of cell therapy, the American Cancer Society say: "Available scientific proof doesn't support claims that cell therapy is effective in treating cancer or every other illness. It may the truth is be lethal ...".[1]

Manufacturing

Despite being one of many fast rising areas inside Life Sciences,[53] the manufacturing of cell therapy merchandise is basically hindered by small scale batches and labour-intensive processes.[54]

Quite a lot of manufacturers are turning to automated strategies of manufacturing, eliminating human involvement and threat of human error. Automated strategies of cell therapy manufacturing have opened up bigger scale manufacturing of higher high quality products at lower cost.[55]

Supply chain

Logistics departments of biopharma companies experience new obstacles because of the introduction of latest cell and gene therapy merchandise, equivalent to Car T-cell therapies and allogeneic therapies. Cell and gene therapies require manufacturer and distributors alike to implement new techniques and processes so as to make sure safe handling and delivery. Additionally, on-demand stock subsequently turns into an increasing number of important, especially with regard to unforeseeable occasions just like the COVID-19 pandemic, so that supply chain interruptions could be prevented.[56] Furthermore latest adjustments on account of the COVID 19 pandemic and political instability in Europe, secondary to Brexit, have additional impacted the logistics chain for cellular therapies. [57]

Stem cellStem cell therapyAllotransplantationAutotransplantationXenotransplantationRegenerative medicationMesenchymal stem cellHematopoietic stem cell transplantationStem cell therapy for macular degeneration
References

^ a b c d e f "Cell Therapy". American Cancer Society. 1 November 2008. Archived from the unique on 26 April 2015. Retrieved 15 September 2013.^ a b Lefrère JJ, Berche P (March 2010). "[Doctor Brown-Sequard's therapy]". Annales d'Endocrinologie. 71 (2): 69-75. doi:10.1016/j.ando.2010.01.003. PMID 20167305.^ a b Starzl TE (July 2000). "History of clinical transplantation". World Journal of Surgery. 24 (7): 759-782. doi:10.1007/s002680010124. PMC 3091383. PMID 10833242.^ Zhou X, Haraldsson T, Nania S, Ribet F, Palano G, Heuchel R, Löhr M, van der Wijngaart W (2018). "Human Cell Encapsulation in Gel Microbeads with Cosynthesized Concentric Nanoporous Solid Shells". Adv. Funct. Mater. 28 (21): 1707129. doi:10.1002/adfm.201707129. hdl:10616/47027. S2CID 104267420.^ "Australian Cancer Research Foundation". Home.cancerresearch. 2014-12-07. Archived from the unique on 2020-02-02. Retrieved 2020-03-22.^ "Health Resources & Services Administration". HRSA.gov. 2020-03-21.^ Gage FH (April 1998). "Cell therapy". Nature. 392 (6679 Suppl): 18-24. PMID 9579857.^ Fuggle NR, Cooper C, Oreffo RO, Price AJ, Kaux JF, Maheu E, et al. (April 2020). "Alternative and complementary therapies in osteoarthritis and cartilage restore". Aging Clinical and Experimental Research. 32 (4): 547-560. doi:10.1007/s40520-020-01515-1. PMC 7170824. PMID 32170710.^ Henchcliffe C, Parmar M (2018-12-18). Brundin P, Langston JW, Bloem BR (eds.). "Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies". Journal of Parkinson's Disease. 8 (s1): S131 - S137. doi:10.3233/JPD-181488. PMC 6311366. PMID 30584166.^ a b Schol J, Sakai D (April 2019). "Cell therapy for intervertebral disc herniation and degenerative disc illness: clinical trials". International Orthopaedics. Forty three (4): 1011-1025. doi:10.1007/s00264-018-4223-1. PMID 30498909. S2CID 53981159.^ Jing D, Parikh A, Canty JM, Tzanakakis ES (December 2008). "Stem cells for coronary heart cell therapies". Tissue Engineering. Part B, Reviews. 14 (4): 393-406. doi:10.1089/ten.teb.2008.0262. PMC 2710610. PMID 18821841.^ Guedan S, Ruella M, June CH (April 2019). "Emerging Cellular Therapies for Cancer". Annual Review of Immunology. 37 (1): 145-171. doi:10.1146/annurev-immunol-042718-041407. PMC 7399614. PMID 30526160.^ Brindley DA, Reeve BC, Sahlman WA, Bonfiglio GA, Davie NL, Culme-Seymour EJ, Mason C (November 2011). "The influence of market volatility on the cell therapy trade". Cell Stem Cell. 9 (5): 397-401. doi:10.1016/j.stem.2011.10.010. PMID 22056137.^ Mason C, Brindley DA, Culme-Seymour EJ, Davie NL (May 2011). "Cell therapy trade: billion greenback international enterprise with limitless potential". Regenerative Medicine. 6 (3): 265-272. doi:10.2217/rme.11.28. PMID 21548728.^ Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, et al. (June 2001). "Regeneration of ischemic cardiac muscle and vascular endothelium by grownup stem cells". The Journal of Clinical Investigation. 107 (11): 1395-1402. doi:10.1172/jci12150. PMC 209322. PMID 11390421.^ Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, et al. (December 2004). "Nonhematopoietic mesenchymal stem cells could be mobilized and differentiate into cardiomyocytes after myocardial infarction". Blood. 104 (12): 3581-3587. doi:10.1182/blood-2004-04-1488. PMID 15297308.^ a b Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. (March 2000). "Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization". Proceedings of the National Academy of Sciences of the United States of America. Ninety seven (7): 3422-3427. Bibcode:2000PNAS...97.3422K. doi:10.1073/pnas.97.7.3422. PMC 16255. PMID 10725398.^ Hiraishi S, Schol J, Sakai D, Nukaga T, Erickson I, Silverman L, et al. (June 2018). "Discogenic cell transplantation directly from a cryopreserved state in an induced intervertebral disc degeneration canine mannequin". JOR Spine. 1 (2): e1013. doi:10.1002/jsp2.1013. PMC 6686803. PMID 31463441.^ Wang W, Deng G, Qiu Y, Huang X, Xi Y, Yu J, et al. (May 2018). "Transplantation of allogenic nucleus pulposus cells attenuates intervertebral disc degeneration by inhibiting apoptosis and growing migration". International Journal of Molecular Medicine. Forty one (5): 2553-2564. doi:10.3892/ijmm.2018.3454. PMC 5846671. PMID 29436582.^ "2017 TERMIS - Americas Conference & Exhibition Charlotte, NC December 3-6, 2017". Tissue Engineering. Part A. 23 (S1): S1 - S159. December 2017. doi:10.1089/ten.tea.2017.29003.abstracts. hdl:1842/35967. PMID 29173019. S2CID 146034988.^ von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H, et al. (April 2012). "Long-term complications, immunologic results, and function of passage for final result in mesenchymal stromal cell therapy". Biology of Blood and Marrow Transplantation. 18 (4): 557-564. doi:10.1016/j.bbmt.2011.07.023. PMID 21820393.^ Deuse, T., C. Peter, et al. (2009). "Hepatocyte progress factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based mostly myocardial salvage after acute myocardial infarction." Circulation 120(eleven Suppl): S247-54.^ Kelly ML, Wang M, Crisostomo PR, Abarbanell AM, Herrmann JL, Weil BR, Meldrum DR (June 2010). "TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac safety following acute ischemia". Shock. 33 (6): 602-607. doi:10.1097/shk.0b013e3181cc0913. PMC 3076044. PMID 19953003.^ Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, Yarmush ML (2010). "Mesenchymal stem cells: Mechanisms of immunomodulation and homing". Cell Transplantation. 19 (6): 667-679. doi:10.3727/096368910x508762. PMC 2957533. PMID 20525442.^ Nugent HM, Ng YS, White D, Groothius A, Kanner G, Edelman ER (December 2009). "Delivery site of perivascular endothelial cell matrices determines management of stenosis in a porcine femoral stent mannequin". Journal of Vascular and Interventional Radiology. 20 (12): 1617-1624. doi:10.1016/j.jvir.2009.08.020. PMC 2788031. PMID 19854069.^ Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM (2009). "The function of placental-derived adherent stromal cell (PLX-PAD) in the therapy of important limb ischemia". Cytotherapy. 11 (4): 427-434. doi:10.1080/14653240902849762. PMID 19526389.^ "Allogeneic Stem Cell Transplant". WebMD. Retrieved 15 September 2013.^ Brandenberger R, Burger S, Campbell A, Fong T, Lapinskas E, Rowley JA (2011). "Cell Therapy Bioprocessing: Integrating Process and Product Development for the following Generation of Biotherapeutics" (PDF). BioProcess International. 9 (suppl. I): 30-37.^ Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A (June 2009). "Treatment of inflammatory diseases with mesenchymal stem cells". Inflammation & Allergy - Drug Targets. Eight (2): 110-123. CiteSeerX 10.1.1.323.3687. doi:10.2174/187152809788462635. PMID 19530993.^ Mays RW, van't Hof W, Ting AE, Perry R, Deans R (February 2007). "Development of grownup pluripotent stem cell therapies for ischemic injury and illness". Expert Opinion on Biological Therapy. 7 (2): 173-184. doi:10.1517/14712598.7.2.173. PMID 17250456. S2CID 22258887.^ Yamasaki S, Mera H, Itokazu M, Hashimoto Y, Wakitani S (October 2014). "Cartilage Repair With Autologous Bone Marrow Mesenchymal Stem Cell Transplantation: Review of Preclinical and Clinical Studies". Cartilage. 5 (4): 196-202. doi:10.1177/1947603514534681. PMC 4335770. PMID 26069698.^ Linard C, Brachet M, L'homme B, Strup-Perrot C, Busson E, Bonneau M, et al. (November 2018). "Long-time period effectiveness of local BM-MSCs for skeletal muscle regeneration: a proof of concept obtained on a pig mannequin of severe radiation burn". Stem Cell Research & Therapy. 9 (1): 299. doi:10.1186/s13287-018-1051-6. PMC 6225585. PMID 30409227.^ Mochida J, Sakai D, Nakamura Y, Watanabe T, Yamamoto Y, Kato S (March 2015). "Intervertebral disc restore with activated nucleus pulposus cell transplantation: a three-12 months, prospective clinical study of its safety". European Cells & Materials. 29: 202-12, dialogue 212. doi:10.22203/eCM.v029a15. PMID 25794529.^ Meisel HJ, Ganey T, Hutton WC, Libera J, Minkus Y, Alasevic O (August 2006). "Clinical experience in cell-primarily based therapeutics: intervention and consequence". European Spine Journal. 15 (Suppl 3): S397 - S405. doi:10.1007/s00586-006-0169-x. PMC 2335385. PMID 16850291.^ Zhong R, Platt JL (November 2005). "Current standing of animal-to-human transplantation". Expert Opinion on Biological Therapy. 5 (11): 1415-1420. doi:10.1517/14712598.5.11.1415. PMC 1475507. PMID 16255645.^ D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick Ad, Smart NG, et al. (November 2006). "Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells". Nature Biotechnology. 24 (11): 1392-1401. doi:10.1038/nbt1259. PMID 17053790. S2CID 11040949.^ Parish CL, Arenas E (2007). "Stem-cell-based mostly methods for the remedy of Parkinson's disease". Neuro-Degenerative Diseases. 4 (4): 339-347. doi:10.1159/000101892. PMID 17627139. S2CID 37229348.^ Bonnamain V, Neveu I, Naveilhan P (2012). "Neural stem/progenitor cells as a promising candidate for regenerative therapy of the central nervous system". Frontiers in Cellular Neuroscience. 6: 17. doi:10.3389/fncel.2012.00017. PMC 3323829. PMID 22514520.^ a b Oh SKW and Choo ABH (2011) "The Biological Basis | Stem Cells". In: Murray Moo-Young (ed.), Comprehensive Biotechnology, Second Edition, Volume 1, pp. 341-65. Elsevier.[ISBN missing]^ Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. (March 1999). "Transplantability and therapeutic results of bone marrow-derived mesenchymal cells in kids with osteogenesis imperfecta". Nature Medicine. 5 (3): 309-313. doi:10.1038/6529. PMID 10086387. S2CID 38011739.^ Le Blanc K, Götherström C, Ringdén O, Hassan M, McMahon R, Horwitz E, et al. (June 2005). "Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with extreme osteogenesis imperfecta". Transplantation. 79 (11): 1607-1614. doi:10.1097/01.tp.0000159029.48678.93. PMID 15940052. S2CID 7040451.^ Koç ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W (August 2002). "Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)". Bone Marrow Transplantation. 30 (4): 215-222. doi:10.1038/sj.bmt.1703650. PMID 12203137.^ Thomas ED, Lochte HL, Cannon JH, Sahler OD, Ferrebee JW (October 1959). "Supralethal whole body irradiation and isologous marrow transplantation in man". The Journal of Clinical Investigation. 38 (10 Pt 1-2): 1709-1716. doi:10.1172/jci103949. PMC 444138. PMID 13837954.^ Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R (November 1998). "Role of members of the Wnt gene household in human hematopoiesis". Blood. 92 (9): 3189-3202. doi:10.1182/blood.V92.9.3189. PMID 9787155. S2CID 227264894.^ Wilson A, Trumpp A (February 2006). "Bone-marrow haematopoietic-stem-cell niches". Nature Reviews. Immunology. 6 (2): 93-106. doi:10.1038/nri1779. PMID 16491134. S2CID 205489817.^ Hwang WY (September 2004). "Haematopoietic graft engineering". Annals of the Academy of Medicine, Singapore. 33 (5): 551-558. PMID 15531949.^ Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, et al. (February 2001). "Sonic hedgehog induces the proliferation of primitive human hematopoietic cells by way of BMP regulation". Nature Immunology. 2 (2): 172-180. doi:10.1038/84282. PMID 11175816. S2CID 27907370.^ Sharma S, Gurudutta GU, Satija NK, Pati S, Afrin F, Gupta P, et al. (December 2006). "Stem cell c-Kit and HOXB4 genes: crucial roles and mechanisms in self-renewal, proliferation, and differentiation". Stem Cells and Development. 15 (6): 755-778. doi:10.1089/scd.2006.15.755. PMID 17253940.^ Thomas ED, Storb R (October 1970). "Technique for human marrow grafting". Blood. 36 (4): 507-515. doi:10.1182/blood.V36.4.507.507. PMID 4916999.^ Hashimoto H, Olson EN, Bassel-Duby R (October 2018). "Therapeutic approaches for cardiac regeneration and restore". Nature Reviews. Cardiology. 15 (10): 585-600. doi:10.1038/s41569-018-0036-6. PMC 6241533. PMID 29872165.^ Gamble A, Pepper AR, Bruni A, Shapiro AM (March 2018). "The journey of islet cell transplantation and future growth". Islets. 10 (2): 80-94. doi:10.1080/19382014.2018.1428511. PMC 5895174. PMID 29394145.^ Barrett S (21 August 2003). "Cellular Therapy". Quackwatch. Retrieved 15 September 2013.^ "Growth in Sales of Products In Cell Therapy and Tissue Engineering". ebers Medical.^ "Scaling Up Cell Therapy Manufacturing". Genetic Engineering and Biotechnology News. 7 September 2018.^ "Cell Therapy Process Development". Next Generation Therapeutics.^ "Supply Chain Optimization in Cell and Gene Therapies". Single Use Support. 20 December 2021.^ Hennessy C, Deptula M, Hester J, Issa F (2023). "Barriers to Treg therapy in Europe: From manufacturing to regulation". Frontiers in Medicine.